Vedolizumab is used to treat moderate to severe ulcerative colitis and Crohn’s disease in adults who have been intolerant to corticosteroids and TNF antagonists. It is also useful in patients in which TNF antagonists do not show desired efficacy. In some patients, it also might be suggested as a first-line treatment. Although various researches have…
Entyvio vs Humira (Vedolizumab Vs Adalimumab) is a head to head comparison of the two tumor necrosis factor inhibitors (TNF inhibitors) in the treatment of patients with inflammatory bowel diseases. Entyvio is a humanized IgG1 monoclonal antibody that acts against α4β7 integrin which plays a main role in gastrointestinal inflammation. While Humira is a TNF…
Entyvio vs Remicade compares the two drugs that target the tumor necrosis factor pathway. Entyvio is the brand name of Vedolizumab and is indicated primarily for the treatment of Crohn’s disease and ulcerative colitis. Remicade is infliximab indicated for autoimmune rheumatic conditions. Remicade is a chimeric monoclonal IgG1 antibody that inhibits TNF-α, which is the…
